Introduction
Erectile dysfunction is germane to hypertensive patients with vascular remodelling of the large capacitance and muscle arteries. Sexual dysfunction is one of the major obstacles to compliance in the antihypertension treatment. 1 Some physicians are reluctant to investigate sexual function, because patients may be embarrassed speaking about their impotence. It has been shown that some specific classes of antihypertensive drugs have a major influence on sexual dysfunction such as diuretics, 2-5 methyldopa, 6 clonidine 7, 8 and b-blockers, mainly nonselective b-blockers. 6, 7, [9] [10] [11] [12] Modern antihypertension therapy should have no impact on sexual activity and should even enhance sexual performance and, thus, quality of life. Calcium channel-blockers and angiotensin-converting enzyme inhibitors (ACE-I) should have less undesirable effects on sexual activity. 6, [11] [12] [13] [14] In a recent study, the AT1-receptor antagonist valsartan and the a and b blocking agent, carvedilol, were compared with regard to their effects on sexual function in a group of newly diagnosed, and untreated hypertensive men. Carvedilol caused a decrease in sexual activity, whereas valsartan was associated with an increase. 15 The purpose of the present study was to evaluate the effect of valsartan or its combination with hydrochlorothiazide (HTZ) on sexual activity in hypertensive men.
Patients and methods
This prospective study, from November 1999 to December 2000, was carried out in 2202 patients with arterial hypertension. The study was supported by an educational grant of Novartis Pharma Schweiz AG, Bern. Of these 2202 patients, 913 had a newly diagnosed hypertension, whereas the others had a previously known history of high blood pressure. Hypertension was defined as a systolic pressure (SBP) X140 mmHg and a diastolic pressure (DBP) X95 mmHg. Patients with DBP4110 mmHg were not included. Mean age was 53 7 8 years, ranging from 40 to 60 years. Data of the present study were collected through a questionnaire (Figure 1 ), which was filled out by the treating physician in the presence of the patient. Written informed consent was obtained from all patients. Patient data were strictly anonymized. A total of three visits was performed within a time period of 16 weeks, that is, a baseline and two follow-up visits at 8 and 16 weeks, respectively. At each visit, blood pressure was measured and antihypertensive therapy adjusted when BP was still 4140/95 mmHg. At the same time, the questionnaire was filled out by the treating physician (Figure 1 ). Questions were asked with regard to general health, medication, sexual activity, satisfaction, sexual intercourses per week and general well-being. A total of 409 general practitioners and internists participated in this trial. Each doctor was asked to include on an average four to five patients. All patients were either married or had a stable relationship with a sexually active partner. During the observation study of 16 weeks, there was no use of sexually stimulating medications. Follow-up was obtained in 2171 patients. These patients were stratified into three groups according to the antihypertensive treatment:
Group 1 consisted of 1899 patients, who received valsartan 80 mg once daily increasing to 160 mg after the second visit in case blood pressure remained elevated.
Group 2 consisted of 276 patients, who received valsartan 80 mg in combination with HTZ 12.5 mg. In case blood pressure remained elevated at the first visit, valsartan was increased to 160 mg, whereas HTZ was unchanged. Figure 1 Questionnaire for assessing sexual activity in patients with hypertension.
Sexual activity and hypertension A Della Chiesa et al Group 3 consisted of 27 patients, who did not receive valsartan and remained on conventional therapy. These patients were asked to take their medication regularly (noncompliance), because they were not willing to change or start on a new drug; 48% of these patients were on b-blockers, 24% on ACE-inhibitors, 11% received calcium channelblockers and 17% were on diuretics.
Statistics
Only complete questionnaires were analysed. Data are given as mean values 7 1 standard error. However, data on sexual intercourse were averaged and given as percentage of the mean. Subgroups were formed according to sexual intercourse per week or age: p47 years/48-53 years/54-58 years/ X59 years. Statistical evaluation was carried out according to the 'intention-to-treat' principle. Intragroup comparisons (baseline, 8 and 16 weeks follow-up) were carried out by an analysis of variance for repeated measurements. Intergroup comparisons were performed with an unpaired Student's t-test. A P-value of o0.05 was considered to be significant.
Results
Mean baseline SBP was 159 mmHg and DBP was 98 mmHg (Table 1) . Mean weight was 83 kg. Baseline medications are listed in Table 1 . A total of 913 patients had no pretreatment and the others were either on b-blockers (44%), ACE-inhibitors (29%), diuretics (21%), calcium channel-blockers (19%), AT1-receptor antagonists (10%) or on a combination of these drugs. There were 26 drop outs, who did not come back to the visits or refused to take the drug.
Effect of medical therapy on arterial hypertension
Mean SBP and DBP decreased significantly in all the three groups (Figure 2 ). The decrease in SBP was approximately 9% during the first 8 weeks and 12% during the whole observation period. There were no differences between the three groups. DBP decreased to a similar extent ( Table 2) .
Effect of medical therapy on sexual activity
At baseline, sexual activity was similar in the three groups ( Figure 3 (Figure 4) , that is, an increase of 45% in the group p47 years, 62% in the group 48-53 years, 73% in the group 54-58 years and 80% in the group X59 years, respectively. In general, younger patients (p47 years) had more intercourses per week than elderly patients (X59 years). Sexual activity per week was unchanged in those with a high activity (five times per week), but increased significantly in those who had sexual intercourses 2-4 times per week. (Figure 5 ). Those who had 0-1 time sexual intercourse per week remained unchanged and it decreased in those who had no sexual intercourse per week. Both newly diagnosed (+34%) as well as pretreated patients (+97%) had an improvement in sexual activity (mean 60%). The most amazing influence of valsartan on sexual intercourse per week was observed in patients of group 1 who had previous treatment. At the first visit (baseline), they had less sexual intercourses per week compared to those who had no pretreatment. During follow-up, the increase in sexual intercourses per week was larger in patients who had pretreatment than those who had not. There was an age-dependent pattern in sexual activity during valsartan treatment: the age group p47 years had the largest increase, from 1.0 at baseline to 2.1 intercourses per week after 16 weeks of valsartan therapy. This represents an increase of approximately 108%. The age group 48-53 years had an increase of 94% during valsartan treatment, 
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Adverse events
One major adverse event occurred, namely angioneurotic oedema of the mouth. However, after stopping the study medication the patient had no further symptoms. There were only a few minor side effects (six of 2202) such as angina pectoris, headache, cough, palpitations and gastralgia.
Discussion
Erectile dysfunction is common in industrialized Western countries ranging between 2 and 5%. Influence of age on sexual activity in hypertensive males treated with valsartan. Younger (p47 years; squares) patients showed significant higher sexual activity than elderly patients (X59 years; circles). Those between 48 and 59 years of age also showed an improvement in sexual activity.
Sexual activity and hypertension A Della Chiesa et al spinal cord injuries 5%, etc. The prevalence increases with age, and is one of the major reasons for a reduced quality of life. One of the major reasons for impaired sexual activity is erectile dysfunction, but other factors may influence sexual activity as well such as general well-being, psychologic disorders, severe diseases affecting general condition, medication and partnership. For instance, the incidence of sexual dysfunction is largely dependent on drug treatment in patients with arterial hypertension, 1,16 myocardial infarction and heart failure. Drugs such as b-blockers 6,7,9-12,18 or diuretics 4,13 influence sexual activity adversely and are often the reason for malcompliance of these patients. 13, 14, 15, 17, 18, 20 Long-term drug treatment for hypertension or heart failure has to take the potential reduction in quality of life into consideration. 20 New antihypertensive drugs such as AT1-receptor antagonists may not have these side effects. Specifically, valsartan 18, 19 has been shown even to enhance sexual activity in patients with hypertension. In a large prospective trial, we evaluated incidence of sexual dysfunction and treatment success of valsartan on sexual activity in 2202 hypertensive patients. From this analysis, the following observations were made:
1. No sexual intercourse is a common finding in hypertensive patients (21%). Erectile dysfunction may account for part of it. 2. The AT1-receptor antagonist valsartan influences sexual dysfunction in a beneficial way and increases the rate of sexual intercourse by approximately 60%. 3. The AT1-receptor antagonist valsartan improves sexual activity in hypertensive patients, whereas sexual activity decreases under conventional therapy.
The cause of sexual dysfunction is often unknown, but treatment remains difficult. It has been shown that under b-blocker therapy, plasma testosterone decreases significantly from 524 to 398 ng/ dl, 19 whereas under valsartan, testosterone levels remained unchanged or even increased slightly. This sheds some light on the pathophysiologic mechanism of these drugs, indicating that b-blockers do not necessarily act through its negative effect on physical activity (fatigue) but through a direct action on sex hormone production. This adverse effect was not observed with the AT1-receptor antagonist valsartan. In another experimental study, intracavernosal injection of angiotensin II caused contraction of cavernosal smooth muscle and terminated spontaneous erection, whereas administration of an AT1-receptor antagonist resulted in smooth muscle relaxation and, thus, erection. This suggests that angiotensin II is an important modulator of erectile function. 21 Effect of valsartan on blood pressure SBP decreased to a similar degree in all the three groups from 160 to 141 mmHg, whereas DBP decreased slightly less from 98 to 86 mmHg ( Figure  2 ). The combination of valsartan with HTZ was not more effective than with monotherapy alone, indicating that these patients do not profit from a combination therapy.
These data suggest that each patient should be treated individually until an optimal blood pressure is reached; for instance, start with valsartan 80 mg, increase to 160 mg and add HTZ when necessary. Conventionally treated patients showed a blood pressure reduction similar to the other two groups.
Age and sexual activity
Younger patients (p47 years) show a higher sexual activity than older ones (X59 years), the mean being 1.5. for the first and 0.7 times/week for the latter group (Po0.05). However, all age groups ( Figure 4) showed a significant increase in sexual activity during the observation period of 16 weeks. Mean increase was 60%, ranging between 80% in the older and 44% in the younger age group. This difference is relative and dependent on the baseline values. The largest increase was observed in young patients who were on conventional therapy prior to inclusion. A similar effect was observed in pretreated and newly diagnosed patients, although the effect was larger in pretreated ones. This can be explained by the negative effect of the antihypertensive treatment before starting with valsartan.
Limitations
Several possible limitations have to be considered for the purpose of the present study:
1. In the present analysis, only male patients were included due to obvious reasons, but female patients may have experienced a similar beneficial effect with regard to libido under valsartan treatment. 2. The control group with conventional therapy is rather small and may not reflect true changes under antihypertensive treatment. However, these patients showed a decrease in sexual activity, whereas valsartan-treated patients showed an increase. 3. General well-being may have influenced sexual activity itself, such as questions regarding sexual activity by the physician, regular visits and optimal treatment of hypertension. 4. There may be a certain bias with regard to the use of a questionnaire, since patients may have been influenced by the presence of their physicians to impress the physician. However, an anonymous evaluation would have had a similar risk of false answers.
5. The combination of valsartan with a thiazide may adversely affect sexual activity, because thiazides are likely to induce erectile dysfunction and, thus, may have diminished the beneficial effect of valsartan. Indeed, the increase in sexual activity was somewhat less in those patients treated with a combination of valsartan plus thiazide than those on valsartan alone.
In conclusions, our data suggest that valsartan reduces both SBP and DBP but improves sexual dysfunction significantly in patients with arterial hypertension. Best effects were seen in young patients and those with drug-induced sexual dysfunction.
